Search Results for "cancer"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cancer. Results 111 to 120 of 171 total matches.
Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
concentrations and renal function
BCRP = breast cancer resistance protein; DAA = direct-acting antiviral drug ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175 doi:10.58347/tml.2024.1714f | Show Introduction Hide Introduction
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
Decreased risk of ovarian and
endometrial cancer, PID, and
dysmenorrhea; cycle control
Increased risk ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
, strong
CYP2C8 inhibitors or inducers, or breast cancer resistance protein
(BCRP) inhibitors.
How ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
for treatment of severe
chronic cancer pain.
DOSAGE — Opioid dosage requirements vary widely
among patients ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Avapritinib (Ayvakit) for GIST
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
Options
Oncol 2020; 21:55.
4. Regorafenib (Stivarga) for metastatic colon cancer and GIST.
Med Lett ...
The FDA has approved the oral tyrosine kinase
inhibitor avapritinib (Ayvakit – Blueprint Medicines)
for treatment of unresectable or metastatic gastrointestinal
stromal tumors (GISTs) harboring a
platelet-derived growth factor receptor alpha
(PDGFRA) D842V or other PDGFRA exon 18 mutation.
Avapritinib is the first drug to be approved for this
indication in the US.
Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
-glycoprotein (P-gp)
and is a moderate inhibitor of CYP2C8 and breast
cancer resistance protein (BCRP ...
The Bruton's tyrosine kinase (BTK) inhibitor
pirtobrutinib (Jaypirca – Lilly) has received
accelerated approval from the FDA for treatment of
relapsed or refractory mantle cell lymphoma (MCL) in
adults who received ≥2 prior lines of systemic therapy,
including a BTK inhibitor. Accelerated approval was
based on the response rate. The BTK inhibitors
ibrutinib (Imbruvica), acalabrutinib (Calquence),
and zanubrutinib (Brukinsa) are also approved for
treatment of MCL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e35-6 doi:10.58347/tml.2023.1670f | Show Introduction Hide Introduction
Belzutifan (Welireg) for Advanced Renal Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
. www.fdbhealth.com/drug-pricing-policy. Afinitor everolimus renal cell cancer Welireg belzutifan ...
Belzutifan (Welireg – Merck), a first-in-class hypoxia-inducible
factor inhibitor, has been approved by the
FDA for treatment of advanced renal cell carcinoma
(RCC) in adults who received prior treatment with a
programmed death receptor-1 (PD-1) or programmed
death-ligand 1 (PD-L1) inhibitor and a vascular
endothelial growth factor tyrosine kinase inhibitor
(VEGF-TKI). Belzutifan was previously approved for
use in patients with von Hippel-Lindau disease.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e75-6 doi:10.58347/tml.2024.1701g | Show Introduction Hide Introduction
Leuprolide Acetate (Fensolvi) for Central Precocious Puberty (online only)
The Medical Letter on Drugs and Therapeutics • Sep 23, 2021 (Issue 1634)
. www.fdbhealth.com/drug-pricing-policy.
2. Also available in various strengths for treatment of prostate cancer.
3 ...
Fensolvi (Tolmar), a long-acting subcutaneous formulation
of the gonadotropin-releasing hormone (GnRH)
agonist leuprolide acetate, has been approved by the
FDA for treatment of central precocious puberty (CPP)
in children ≥2 years old. It is the first formulation of
the drug to be approved for SC administration once
every 6 months. IM formulations of leuprolide acetate,
which are given once monthly or every 3 months, and
the GnRH agonists histrelin acetate (Supprelin LA) and
triptorelin (Triptodur) have been available for years for
treatment of CPP.
A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
and
proliferation and secretion of inflammatory cytokines,
which leads to T-cell-mediated destruction of
cancer ...
The FDA recently approved axicabtagene ciloleucel
(Yescarta – Kite), a CD19-directed genetically
modified cellular product, for treatment of large B-cell
lymphoma that is refractory to first-line chemoimmunotherapy
or that relapses within 12 months
of first-line treatment. It was previously approved for
treatment of relapsed or refractory B-cell lymphoma
after ≥2 lines of systemic therapy and for treatment
of relapsed or refractory follicular lymphoma
after ≥2 lines of systemic therapy. Yescarta is an
individualized cellular product prepared from the
patient's own T cells,...
In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
of inflammatory cytokines,
which leads to T-cell-mediated destruction of cancer
cells.
CLINICAL STUDIES — FDA ...
The FDA has approved lisocabtagene maraleucel
(Breyanzi – BMS) for treatment of adults with large
B-cell lymphoma (LBCL), including diffuse large
B-cell lymphoma (DLBCL) not otherwise specified,
high-grade B-cell lymphoma, primary mediastinal
large B-cell lymphoma, or follicular lymphoma
grade 3B who have disease refractory to first-line
chemoimmunotherapy, relapsed within 12 months
of or after first-line chemoimmunotherapy, are not
eligible for hematopoietic stem cell transplantation
due to comorbidities or age, or have relapsed
or refractory disease after ≥2 lines of...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e104-5 doi:10.58347/tml.2023.1679f | Show Introduction Hide Introduction